The specialty anesthesia company, Primex Pharmaceuticals AG, has turned its attention to the US development of its novel oral midazolam solution for use in children, following the approval of the product, as Ozalin, in the EU last month.
Ozalin was approved through the EU's decentralized procedure and national approvals are now being pursued, with the first markets for the pediatric moderate sedative agent likely to be the UK and the Nordic